• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparisons of Real-World Time-to-Event End Points in Oncology Research.

作者信息

Walker Brigham, Boyd Marley, Aguilar Kat, Davies Kalatu, Espirito Janet, Frytak Jennifer, Robert Nicholas

机构信息

Brigham Walker, PhD, Ontada, Irving TX, Tulane University, New Orleans, LA; and Marley Boyd, MS, Kat Aguilar, MPH, Kalatu Davies, PhD, Janet Espirito, PharmD, Jennifer Frytak, PhD, and Nicholas Robert, MD, Ontada, Irving TX.

出版信息

JCO Clin Cancer Inform. 2021 Jan;5:45-46. doi: 10.1200/CCI.20.00125.

DOI:10.1200/CCI.20.00125
PMID:33411622
Abstract
摘要

相似文献

1
Comparisons of Real-World Time-to-Event End Points in Oncology Research.肿瘤学研究中真实世界事件发生时间终点的比较。
JCO Clin Cancer Inform. 2021 Jan;5:45-46. doi: 10.1200/CCI.20.00125.
2
End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.免疫肿瘤学试验的终点和统计学考虑因素：对多发性骨髓瘤的影响。
Future Oncol. 2017 Jun;13(13):1181-1193. doi: 10.2217/fon-2016-0504. Epub 2017 Apr 11.
3
Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?受限平均生存时间：癌症试验中事件发生时间分析的必要终点？
J Clin Oncol. 2016 Oct 1;34(28):3474-6. doi: 10.1200/JCO.2016.67.8045. Epub 2016 Aug 9.
4
Using a Clinically Interpretable End Point Composed of Multiple Outcomes to Evaluate Totality of Treatment Effect in Comparative Oncology Studies.在比较肿瘤学研究中，使用由多个结果组成的临床可解释终点来评估治疗效果的总体情况。
JAMA Netw Open. 2023 Jun 1;6(6):e2319055. doi: 10.1001/jamanetworkopen.2023.19055.
5
Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.使用替代终点而非总生存期来估计肿瘤学临床试验中的研究时间缩短。
JAMA Intern Med. 2019 May 1;179(5):642-647. doi: 10.1001/jamainternmed.2018.8351.
6
Response Rate as an Approval End Point in Oncology: Back to the Future.缓解率作为肿瘤学中的批准终点：回归未来。
JAMA Oncol. 2016 Jun 1;2(6):780-1. doi: 10.1001/jamaoncol.2015.6352.
7
Endpoint selection and unreported analgesic use may render oncologic studies inconclusive.终点指标的选择以及未报告的镇痛药物使用可能会使肿瘤学研究结果不明确。
Anesthesiology. 2011 Mar;114(3):717; author reply 718. doi: 10.1097/ALN.0b013e3182084b18.
8
Evolution of clinical trials registries.临床试验注册库的演变。
J Clin Oncol. 2012 Jan 10;30(2):131-3. doi: 10.1200/JCO.2011.39.6051. Epub 2011 Dec 12.
9
N-of-1 trials in oncology.肿瘤学中的单病例试验。
Lancet Oncol. 2015 Aug;16(8):885-6. doi: 10.1016/S1470-2045(15)00062-5.
10
Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review.从注册到发表，肿瘤随机对照试验中主要终点分析和报告的一致性：系统评价。
J Clin Oncol. 2012 Jan 10;30(2):210-6. doi: 10.1200/JCO.2011.37.0890. Epub 2011 Dec 12.

引用本文的文献

1
A Practical Approach to Understanding Real-World Study Methodology in Cancer Research: A Vodcast.癌症研究中理解真实世界研究方法的实用途径：视频播客
Oncol Ther. 2025 Sep 11. doi: 10.1007/s40487-025-00366-y.
2
Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.与晚期间变性淋巴瘤激酶阳性非小细胞肺癌治疗相关的真实世界成本、治疗模式及临床结局
J Manag Care Spec Pharm. 2025 Sep;31(9):890-899. doi: 10.18553/jmcp.2025.31.9.890.
3
Regarding RECIST in retrospective studies.
关于回顾性研究中的实体瘤疗效评价标准（RECIST）。
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf182.
4
Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States.美国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者存在2种或更多种淋巴细胞增多的真实世界特征、治疗模式及预后
Blood Neoplasia. 2024 Oct 14;2(1):100047. doi: 10.1016/j.bneo.2024.100047. eCollection 2025 Feb.
5
Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma.美国转移性去分化脂肪肉瘤患者的真实世界生存结果及MDM2患病率
Future Oncol. 2025 Jun;21(14):1797-1807. doi: 10.1080/14796694.2025.2502319. Epub 2025 Jun 4.
6
Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data.利用健康记录数据对复发/难治性多发性骨髓瘤中基于达雷妥尤单抗的治疗方案进行真实世界比较。
Blood Neoplasia. 2024 Feb 15;1(1):100003. doi: 10.1016/j.bneo.2024.100003. eCollection 2024 Mar.
7
Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed/refractory mantle cell lymphoma in the United States.美国嵌合抗原受体T细胞疗法与标准疗法治疗复发/难治性套细胞淋巴瘤的治疗模式、医疗资源利用及成本
J Manag Care Spec Pharm. 2025 Mar;31(3):262-276. doi: 10.18553/jmcp.2025.31.3.262.
8
Exploring the value of routinely collected data on EQ-5D-5L and other electronic patient-reported outcome measures as prognostic factors in adults with advanced non-small cell lung cancer receiving immunotherapy.探索常规收集的EQ-5D-5L数据及其他电子患者报告结局指标作为接受免疫治疗的晚期非小细胞肺癌成年患者预后因素的价值。
BMJ Oncol. 2024 May 15;3(1):e000158. doi: 10.1136/bmjonc-2023-000158. eCollection 2024.
9
Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer.尼拉帕利一线维持单药治疗上皮性卵巢癌患者的真实世界疗效
Future Oncol. 2025 Jan;21(2):213-219. doi: 10.1080/14796694.2024.2441654. Epub 2025 Jan 17.
10
Treatment of oligometastatic breast cancer: The role of patient selection.寡转移性乳腺癌的治疗：患者选择的作用。
Breast. 2025 Feb;79:103839. doi: 10.1016/j.breast.2024.103839. Epub 2024 Nov 14.